Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders
Status:
Withdrawn
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral
immune response against the aquaporin-4(AQP-4) water channel. Rucotinib is an oral inhibitor
of JAK1 and JAK2 tyrosine kinases. It may benefit some patients with NMOSD due to the
important role of JAK/STAT signaling pathway in the pathogenesis of NMOSD. Clincial trials
may be needed to observe its efficacy and safety.